WATERTOWN, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Findings from an interim analysis showed CELZ-201-DDT statistically significantly reduced pain and improved mobility in patients with chronic lower back pain. The Food and Drug Administration (FDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback